Search research articles
Contact Us
Filters
Showing results (81-90 of 86) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 86 results.
JCO Precision Oncology
|
June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I
Shivaani Kummar, Zihe Song, Kim A Reiss, et al.
The Journal of Molecular Diagnostics : JMD
|
February 12, 2017
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial
Chih-Jian Lih, Robin D Harrington, David J Sims, et al.
Nature Medicine
|
July 21, 2015
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H Wilson, Ryan M Young, Roland Schmitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2019
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study
Michael S Khodadoust, Alain H Rook, Pierluigi Porcu, et al.
JCO Precision Oncology
|
November 6, 2025
Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials
Cloud P Paweletz, Thomas D Forbes, Laura Yee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2025
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Linda K Zane, Laura M Yee, Ting-Chia Chang, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 86) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 86 results.
JCO Precision Oncology
|
June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I
Shivaani Kummar, Zihe Song, Kim A Reiss, et al.
The Journal of Molecular Diagnostics : JMD
|
February 12, 2017
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial
Chih-Jian Lih, Robin D Harrington, David J Sims, et al.
Nature Medicine
|
July 21, 2015
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H Wilson, Ryan M Young, Roland Schmitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2019
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study
Michael S Khodadoust, Alain H Rook, Pierluigi Porcu, et al.
JCO Precision Oncology
|
November 6, 2025
Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials
Cloud P Paweletz, Thomas D Forbes, Laura Yee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2025
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Linda K Zane, Laura M Yee, Ting-Chia Chang, et al.
Page
of 9